Newsroom
Featured News
- Business05 September 2022
Lotus Launches Lenalidomide Capsules 5mg, 10mg, 15mg, and 25mg, Generic Version of Revlimid® in the US
- Business16 January 2023
Lotus Obtains Tentative Approval for Nintedanib ANDA from the US FDA
- Investors10 January 2023
Lotus Ends 2022 on a Strong Note, with Full Year Revenue up 15.7% over Last Year
- Business05 January 2023
Lotus Obtained Another Exclusive Right of Cancer Injectable Drug Across Asia
- Business29 December 2022
Alvogen Korea ISO37001 (ANTI-BRIBERY MANAGEMENT SYSTEM) certification renewal
- Business13 December 2022
Lotus acquires Alimta® (Pemetrexed) in Taiwan from Lilly
- Investors09 December 2022
Monthly sales report for November 2022
- Business01 December 2022
Lotus Received Corporate Excellence Award at the Asia Pacific Enterprise Awards (APEA) 2022
- Business30 November 2022
Alvogen Korea held a meeting with the Iceland Minister of Culture and Business Affairs during her visit to Korea
- Investors10 November 2022
Lotus Reports Its Best Quarter Ever With the Biggest Launch in Its History
